Impact of Left Atrial Appendage Closure With a Closure Device on Quality of Life, Physical Capacity and Expression of Atrial Natriuretic Peptide and Brain Natriuretic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atrial Fibrillation
- Sponsor
- University of Leipzig
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- exercise capacity measured by maximal oxygen consumption
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Closure of the left atrial appendage in patients with atrial fibrillation and risk for stroke is a increasing technology leading to exclusion of the left atrial appendage volume from the blood circulation and therefore protects from cardioembolic strokes- It is unclear if the volume reduction of the left atrium leads to a change in exercise capacity or Quality of life.
Detailed Description
The monocentric trial deals with the endocrinological changes as a result of closure of the left atrial appendage with a internal closure device. Specially, the changes in atrial natriuretic peptide, brain natriuretic peptide and their impact on exercise capacity is on focus of the trial. The trial is planned as a all comers trial.
Investigators
Sven Möbius-Winkler
PD Dr. med.
University of Jena
Eligibility Criteria
Inclusion Criteria
- •Patient with a indication for LAA closure device Implantation
Exclusion Criteria
- •Inability to perform exercise testing
Outcomes
Primary Outcomes
exercise capacity measured by maximal oxygen consumption
Time Frame: Baselina, 45 days, 6 months
Change from baseline spiroergometry to 45 days to 6 months